Tissue plasminogen activator (tPA) is administered after ischemic stroke to dissolve intravascular clots, but its use can lead to hemorrhagic transformation (HT). Therapeutic strategies to reduce hemorrhagic complications of tPA might be of benefit for stroke patients. Adenosine A2b receptor (A2bR) plays pivotal roles in regulating vascular protection in peripheral organs. This study explored whether A2bR agonist BAY 60-6583 reduces hemorrhage risk after tPA usage. Using a rat transient middle cerebral artery occlusion model, we showed that mRNA and protein expression of A2bR increased to a greater extent after ischemia-reperfusion than did expression of the other three adenosine receptors (A1, A2a, and A3). tPA administration reduced A2bR expression in ischemic brain microvessels. Post-treatment with BAY 60-6583 (1 mg/kg) at the start of reperfusion reduced lesion volume in the absence or presence of tPA (10 mg/kg) and attenuated brain swelling, blood-brain barrier disruption, and tPA-exacerbated HT at 24 h. Additionally, BAY 60-6583 mitigated sensorimotor deficits in the presence of tPA. BAY 60-6583 inhibited tPA-enhanced matrix metalloprotease-9 activation, probably through elevation of tissue inhibitor of matrix metalloproteinases-1 expression, and thereby reduced degradation of tight junction proteins. These effects would likely protect cerebrovascular integrity. A2bR agonists as an adjuvant to tPA could be a promising strategy for decreasing the risk of HT during treatment for ischemic stroke.
Introduction
The thrombolytic agent tissue plasminogen activator (tPA) is underutilized in ischemic stroke, in part because of its limited therapeutic window and hemorrhagic complications (Kleindorfer et al., 2008; Wang et al., 2015d) . tPA can injure the blood-brain barrier (BBB) by activating matrix metalloproteinases (MMPs) and can increase BBB permeability by degrading extracellular matrix components and tight junction proteins on endothelial cells (Tsuji et al., 2005; Yepes et al., 2009 ).
These effects can lead to hemorrhagic transformation (HT) and aggravate brain damage after reperfusion (Kelly et al., 2006; Mishiro et al., 2012) . Identifying an adjuvant drug that reduces the risk of hemorrhage could increase the applicability of tPA.
Adenosine is a potent neuromodulator that acts through four G-protein-coupled receptors (A1, A2a, A2b, and A3). A1 and A2a are high-affinity receptors that are active under normal physiologic conditions. A2b receptors (A2bRs) are activated by micromolar concentrations of adenosine in tissues that experience ischemia, trauma, inflammation, or other types of stressful insults (Eltzschig, 2009 ). When ischemic conditions trigger a robust and sustained increase in cerebral extracellular levels of adenosine, activation of low-affinity A2bR might protect against ischemic injury.
Studies have shown that the selective A2bR agonist BAY 60-6583 reduces myocardial infarct size in rabbit and mouse hearts when it is administered before or at the onset of reperfusion (Eckle et al., 2007; Kuno et al., 2007; Methner et al., 2010) . Moreover, vascular permeability was increased in peripheral organs of A2bR-null mice that were subjected to hypoxia (Eckle et al., 2008) . BAY 60-6583 treatment reversed vascular leakage induced by hypoxic stress and luminal mechanical injury 
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